Jaime Ordoñez: Researches and Publications

Researches in academic meetings

1. Cost-effectiveness of Omega-3 fatty acids as an adjunct to Simvastatin in the treatment of hypertriglyceridemia. ISPOR (International Society for Pharmacoeconomics and Outcomes Research) 3rd Latin America Conference, 2011, Mexico DF, Mexico.
2. Cost-effectiveness analysis of pregabalin for the treatment of neuropathic pain in Colombia. ISPOR 18th International Annual Meeting, 2013, New Orleans, USA.
3. Cost-effectiveness analysis of prophylaxis versus on-demand supply of factor IX in patients diagnosed with severe hemophilia B in Colombia. ISPOR 18th International Annual Meeting, 2013, New Orleans, USA.
4. Budget impact analysis of apixaban versus enoxaparin in patients undergoing total hip or knee replacement in Colombia. ISPOR 18th International Annual Meeting, 2013, New Orleans, USA.
5. Cost-effectiveness of apixaban in venous trhomboemolism prevention in patients undergoing elective total knee or hip replacement in the Colombian private sector. ISPOR 18th International Annual Meeting, 2013, New Orleans, USA.
6. Economic evaluation of prophylactic treatment versus on demand for severe hemophilia A in Colombia. ISPOR 18th International Annual Meeting, 2013, New Orleans, USA.
7. Cost-effectiveness analysis of vaccination with 13-valent (PCV13) and 23-valent (PPSV23) pneumococcal vaccines for adults in a private Colombian institution. ISPOR 18th International Annual Meeting, 2013, New Orleans, USA.
8. Budget impact of pregabalin for the treatment of neuropathic pain in Colombia. ISPOR 18th International Annual Meeting, 2013, New Orleans, USA.
9. Cost-effectiveness analysis of the available pneumococcal conjugates vaccines for children in Colombia. ISPOR 18th International Annual Meeting, 2013, New Orleans, USA.
10. Cost-effectiveness analysis of vaccination with 13-valent (PCV13) and 23-valent (PPSV23) pneumococcal vaccines for adults in Bogotá, Colombia – Public Scenario. ISPOR 18th International Annual Meeting, 2013, New Orleans, USA.
11. Cost-effectiveness analysis of pregabalin for the treatment of neuropathic pain in Colombia. 58th National Congress of the Colombian Society of Orthopedic Surgery and Traumatology, 2013, Cali, Colombia.
12. Budget impact analysis of pregabalin for the treatment of neuropathic pain in Colombia. 58th National Congress of the Colombian Society of Orthopedic Surgery and Traumatology, 2013, Cali, Colombia.
13. Cost-effectiveness analysis of 13-valent and 23-valent pneumococcal vaccines for high-risk adults in Colombia. ISPOR 4th Latin America Conference, 2013, Buenos Aires, Argentina.
14. Cost-effectiveness analysis of conjugate pneumococcal conjugate vaccines 10 and 13 for children in Antioquia, Colombia. ISPOR 4th Latin America Conference, 2013, Buenos Aires, Argentina.
15. Cost-effectiveness analysis of prophylactic versus on-demand treatment in adolescents with severe hemophilia A in Colombia. ISPOR 4th Latin America Conference, 2013, Buenos Aires, Argentina.
16. Cost-effectiveness analysis of prophylactic versus on-demand treatment in young adults with severe hemophilia A in Colombia. ISPOR 4th Latin America Conference, 2013, Buenos Aires, Argentina.
17. Quality of life with «Dermatology Life Quality Index» in patients with psoriasis: a systematic review. ISPOR 4th Latin America Conference, 2013, Buenos Aires, Argentina.
18. Cost-effectiveness analysis of the use of statins in the prevention of cardiovascular diseases in Colombia. ISPOR 4th Latin America Conference, 2013, Buenos Aires, Argentina (Best Podium Research Presentation Award).
19. Economic evaluation of prophylactic treatment vs on demand for moderate hemophilia A in Colombia. ISPOR 19th International Annual Meeting, 2014, Montreal, Canada.
20. Cost-effectiveness analysis of prophylaxis vs on demand supply of factor IX in patients diagnosed with moderate hemophilia B in Colombia. ISPOR 19th International Annual Meeting, 2014, Montreal, Canada.
21. Cost-effectiveness analysis of pneumococcal conjugate vaccines in Colombia. ISPOR 5th Latin America Conference, 2015, Santiago, Chile.
22. Cost-utility analysis of intramuscular interferon Beta-1a versus subcutaneous interferon Beta-1a and Beta-1b in patients with relapsing-remitting multiple sclerosis in Colombia. ISPOR 21st International Annual Meeting, 2016, Washington DC, USA.
23. Dapagliflozin versus sulfonylureas in patients with type 2 diabetes mellitus in Colombia: cost-effectiveness analysis. ISPOR Colombia, 4th National Meeting, 2016, Bogotá D.C., Colombia (Best Poster Research Award).
24. Cost-utility analysis of intramuscular interferon Beta-1a versus subcutaneous interferon Beta-1a and Beta-1b in patients with relapsing-remitting multiple sclerosis in Colombia. ISPOR Colombia, 4th National Meeting, 2016, Bogotá D.C., Colombia
25. Cost-utility analysis of dimethyl fumarate versus fingolimod and teriflunomide in patients with relapsing-remitting multiple sclerosis in Colombia. ISPOR 19th Annual European Congress, 2016, Vienna, Austria.
26. Dapagliflozin versus inhibitors DPP-4 in patients with type 2 diabetes mellitus in Colombia: a cost-utility analysis. Colombian Society of Health Economics – ACOES, 5th National Meeting, 2016, Bogotá D.C., Colombia (Second Place as Poster Research Award).
27. Exenatide versus insulin glargine in patients with type 2 diabetes mellitus in Colombia: a cost-utility analysis. Colombian Society of Health Economics – ACOES, 5th National Meeting, 2016, Bogotá D.C., Colombia.
28. Cost-utility of dapagliflozin versus DPP4 inhibitors in patients with type 2 diabetes mellitus in Colombia. ISPOR 22nd International Annual Meeting, 2017, Boston (MA), USA.
29. Dapagliflozin versus sulfonylurea in patients with type 2 diabetes mellitus in Colombia: cost-effectiveness analysis. ISPOR 22nd International Annual Meeting, 2017, Boston (MA), USA.
30. Cost-utility of exenatide versus insulin glargine in patients with type 2 diabetes mellitus in Colombia. ISPOR 22nd International Annual Meeting, 2017, Boston (MA), USA.
31. Cost-utility analysis of pegylated interferon beta-1A versus interferons beta-1A and beta-1B in patients with relapsing-remitting multiple sclerosis in Colombia. ISPOR 22nd International Annual Meeting, 2017, Boston (MA), USA.
32. Dimethyl fumarate versus fingolimod and teriflunomide for the treatment of relapsing-remitting multiple sclerosis in Colombia: a cost-utility analysis. ISPOR 22nd International Annual Meeting, 2017, Boston (MA), USA.
33. Cost-utility analysis of trabecular micro-bypass stents versus laser trabeculoplasty for patients with open-angle glaucoma in Colombia. ISPOR 23rd International Annual Meeting, 2018, Baltimore (MD), USA.
34. Cost-utility analysis of iStent trabecular micro-bypass stents versus medications only for patients with open-angle glaucoma in Colombia. ISPOR 23rd International Annual Meeting, 2018, Baltimore (MD), USA.

Publications

Papers

1. González MP, Rivera RC, Vásquez MI, Arias JM, Ordoñez JE. Peripheral nerve block under ultrasound guidance in a patient with implantable cardioverter. Revista Colombiana de Anestesiología. 2009; 37: 79-80.
2. Londoño AM, Gaviria CE, Ordoñez JE. Effectiveness of oral PUVA versus narrow band UVB in psoriasis: meta-analysis. Rev CES Med. 2009; 23: S97-S104.
3. Londoño AM, Gaviria CE, Sánchez M, Ordoñez JE. Comparison of Psoralen plus ultraviolet A (PUVA) and ultraviolet B narrowband (NB-UVB) in the treatment of psoriasis. Rev Fac Nac Salud Pública. 2009; 27: 322-8.
4. González MP, Rivera RC, Ordoñez JE, Rivera JS, Velásquez LF, Pineda C, et al. Clinical evaluation of the quality of endotracheal intubation with remifentanil-propofol-remifentanil-sevoflurane compared with propofol-rocuronium: a randomized clinical trial. Rev Esp Anestesiol Reanim. 2010; 57: 275-80.
5. Cardona D, Estrada A, Chavarriaga LM, Segura AM, Ordoñez JE, Osorio JJ. Dignified social support of the elderly institutionalized. Medellin, 2008. Rev Salud Pública. 2010; 12(3): 414-24.
6. Ordoñez JE, Domínguez RP, Gómez CF, Laguado J, Prada DM. Validation of a survey to assess patient satisfaction in the outpatient. Rev CES Salud Pública. 2010; 1(1): 49-64.
7. Cardona D, Estrada A, Segura AM, Chavarriaga LM, Ordoñez JE, Osorio JJ. The dependence of the institutionalized elderly is a matter of life quality. Medellin, 2008. Rev CES Salud Pública. 2011; 2(1): 3-12.
8. Segura AM, Berbesí D, Cardona D, Ordoñez JE. Preliminary construction of a questionnaire on knowledge on HIV / AIDS in Colombia veterans. Rev Peru Med Exp Salud Pública. 2011; 28(3): 503-7.
9. Estrada A, Cardona D, Segura AM, Chavarriaga LM, Ordoñez JE, Osorio JJ. Quality of life of elderly people in Medellin. Biomédica. 2011; 31(4): 492-502.
10. Rendón DA, Ordoñez JE, Orozco JJ. PCV9 Cost-effectiveness of omega-3 fatty acids as an adjunct of simvastatin in the treatment of hypertriglyceridemia. Value Health. 2011; 13: A545-6.
11. Herrera AM, Echeverri CA, Maya GJ, Ordoñez JE. Respiratory diseases in preschool children and its relation to the concentration of air pollutants in the city of Medellin (Colombia). Rev Ing Univ Medellin. 2011; 10 (19): 21-32.
12. Vélez JM, Berbesí D, Cardona D, Segura AM, Ordoñez JE. Validation of abbreviated Zarit scales for measuring primary syndrome of caregivers of elderly people in Medellin. Aten Primaria. 2012; 44(7): 411-6.
13. Ordóñez JE, Gutiérrez MV, Vargas N. Cost-effectiveness analysis of vaccination with 13-valent (PCV13) and 23-valent (PPSV23) pneumococcal vaccines for adults in a private Colombian institution. Value Health. 2013; 16(3): A90.
14. Ordóñez JE, Gutiérrez MV, Vargas N. Cost-effectiveness analysis of vaccination with 13-valent (PCV13) and 23-valent (PPSV23) pneumococcal vaccines for adults in Bogota, Colombia – Public scenario. Value Health. 2013; 16(3): A90.
15. Ordóñez JE, Orozco JJ. Cost-effectiveness analysis of the available pneumococcal conjugated vaccines for children in Colombia. Value Health. 2013; 16(3): A93.
16. Estrada A, Cardona D, Segura AM, Ordoñez JE, Osorio JJ, Chavarriaga LM. Depressive symptoms institutionalized elderly people and factors associated. Univ Psychol. 2013; 12(1): 81-94.
17. Ordóñez JE, Orozco JJ. Economic evaluation of prophylactic treatment versus on-demand for severe hemophilia A in Colombia. Value Health. 2013; 16(3): A104.
18. Ordóñez JE, Orozco JJ. Cost-effectiveness analysis of prophylaxis versus on-demand supply of factor IX in patients diagnosed with severe hemophilia B in Colombia. Value Health. 2013; 16(3): A104-5.
19. Ordoñez JE, Palacios AU, Londoño AM, Jiménez SB. Assessing quality of life through the Dermatology Life Quality Index in patients with psoriasis: a systematic review. Rev Asoc Colomb Dermatol. 2013; 21(4): 305-13.
20. Ordóñez JE, Orozco JJ, Gutiérrez MV. Budget impact of pregabalin for the treatment of neuropathic pain in Colombia. Value Health. 2013; 16(3): A114.
21. Ordóñez JE, Orozco JJ, Gutiérrez MV. Cost-effectiveness of pregabalin for the treatment of neuropathic pain in Colombia. Value Health. 2013; 16(3): A118.
22. Ordóñez JE, Duque JG, Gutiérrez MV. Economic evaluation of prophylactic treatment versus on demand for moderate hemophilia A in Colombia. Value Health. 2013; 16(3): A228.
23. Ordóñez JE, Garrido S, Vargas N, Juárez A, Mould J, Donato BMK. The cost-effectiveness of apixaban in venous thromboembolism prevention in patients undergoing elective total knee or hip replacement in the Colombian private sector. Value Health. 2013; 16(3): A289.
24. Mould J, Ordóñez JE, Gutiérrez MV, Vargas N. Cost-effectiveness analysis of the use of statins in the prevention of cardiovascular events in Colombia. Value Health. 2013; 16(7): A666.
25. Ordóñez JE, Gutiérrez MV, Vargas N. Cost-effectiveness analysis of pneumococcal 13-valent and 23 valent vaccines for high risk adults in Colombia. Value Health. 2013; 16(7): A667.
26. Ordoñez JE, Palacios AU, Londoño AM, Jiménez SB. Assessing quality of life through the “Dermatology Life Quality Index” in patients with psoriasis: a systematic review. Value Health. 2013; 16(7): A701.
27. Ordóñez JE, Orozco JJ. Cost-effectiveness analysis of pneumococcal conjugated 10-valent and 13-valent vaccines for children in Antioquia, Colombia. Value Health. 2013; 16(7): A713.
28. Ordóñez JE, Orozco JJ. Cost-effectiveness analysis of prophylactic treatment versus on-demand in teenagers with severe hemophilia A in Colombia. Value Health. 2013; 16(3): A721.
29. Ordóñez JE, Orozco JJ. Cost-effectiveness analysis of prophylactic treatment versus on-demand in younger adults with severe hemophilia A in Colombia. Value Health. 2013; 16(3): A721.
30. Cardona A, Ordoñez JE, Vásquez EM, Mestra L, García RA. Effects of early discharge in the postpartum period in Clínica del Prado, Medellin, Colombia. Rev. Geren. Polit. Salud, Bogotá (Colombia). 2014; 13(26): 119-126.
31. Ordóñez JE, Garrido S, Vargas N, Prieto V. Budget impact analysis of apixaban versus enoxaparin in patients undergoing total hip or knee replacement in Colombia. Value Health. 2014; 17(3): A43.
32. Mould JF, Ordoñez JE, Gutiérrez MV, Vargas N. The Cost-Effectiveness of the use of statins in the prevention of cardiovascular events in Colombia. ISPOR Latin American Consortium Newsletter Vol. II Issue I February/March 2014, Pag. 4-6.
33. Ordóñez JE, Duque JG, Gutiérrez MV. Cost-effectiveness analysis of prophylaxis versus on-demand supply of factor IX in patients diagnosed with moderate hemophilia B in Colombia. Value Health. 2014; 17(3): A228.
34. Ordoñez JE, Orozco JJ. Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia. BMC Infectious Diseases. 2014; 14: 172.
35. Mould JF, Gutuérrez MV, Ordoñez JE, Pinsky B, Vargas N. Cost-effectiveness Analysis of Atorvastatin versus Rosuvastatin in Primary and Secondary Cardiovascular Prevention Populations in Brazil and Columbia. Value in Health Regional Issues. 2014; 5: 48-57.
36. Giglio N, Micone P, Ordóñez JE. Cost-effectiveness analysis of pneumococcal conjugated vaccines in Colombia. Value Health. 2015; 18(7): A870-1.
37. Ordoñez JE, Orozco JJ. Cost-effectiveness analysis of the available pneumococcal conjugated vaccines for children under five years in Colombia. Cost Eff Resour Alloc. 2015; 13: 6.
38. Ordóñez JE, Delgado A. Cost-utility analysis of intramuscular interferon Beta-1b versus subcutaneous interferon Beta-1b and Beta-1a in patients with relapsing-remitting multiple sclerosis in Colombia. Value Health. 2016; 19(3): A63.
39. Ordóñez JE, Palacios AU. Cost-effectiveness analysis of Apixaban versus Enoxaparin in patients undergoing total hip or knee replacement in Colombia. Revista Colombiana de Ortopedia y Traumatología. 2016; 30(4): 133-40.
40. Ordóñez JE, Serafini P, Machado M. Cost-utility analysis of dimethyl fumarate versus fingolimod and teriflunomide in patients with relapsing-remitting multiple sclerosis in Colombia. Value Health. 2016; 19(7): A434.
41. Ordoñez JE. Cost-utility of dapagliflozin versus DPP4 inhibitors in patients with type 2 diabetes mellitus in Colombia. Value Health. 2017; 20(5): A172 (PDB52).
42. Ordoñez JE. Dapagliflozin versus sulfonylurea in patients with type 2 diabetes mellitus in Colombia: cost-effectiveness analysis. Value Health. 2017; 20(5): A172 (PDB53).
43. Ordoñez JE. Cost-utility of exenatide versus insulin glargine in patients with type 2 diabetes mellitus in Colombia. Value Health. 2017; 20(5): A172 (PDB54).
44. Ordoñez JE. Cost-utility analysis of pegylated interferon beta-1A versus interferons beta-1A and beta-1B in patients with relapsing-remitting multiple sclerosis in Colombia. Value Health. 2017; 20(5): A193-4 (PND36).
45. Ordoñez JE. Dimethyl fumarate versus fingolimod and teriflunomide for the treatment of relapsing-remitting multiple sclerosis in Colombia: a cost-utility analysis. Value Health. 2017; 20(5): A194 (PND37).
46. Ordóñez JE, Palacios AU. Recombinant factor VIIa and prothrombin complex concentrates to treat bleeding episodes in hemophilic patients with inhibitors: a systematic review. Hematol Transfus Int J. 2018; 6(3): 105-9.

Books

1. Ordoñez JE (editor). Asbestos: A view from the academy. Medellin: CES Editorial; 2009.
2. Berbesí D, Segura AM, Ordoñez JE. Study of prevalence, knowledge, attitudes and practices about HIV on demobilized population of Low Cauca region (Colombia). Medellin: International Organization for Migration, USAID, CES University; 2010.
3. Ordoñez JE. Teaching guide for the implementation of evidence-based Clinical Practice Guidelines (CPG). Bogotá DC: Colombia Department of Health and Social Protection; 2010.
4. Cardona D, Estrada A, Segura AM, Chavarriaga LM, Ordoñez JE, Osorio JJ. Health status analysis of institutionalized older people, Medellin, 2008. Medellin: Editorial CES; 2010.
5. Ordoñez JE. Promoting patient safety culture. Bogotá DC: Colombia Department of Health and Social Protection; 2010.
6. Ordoñez JE. Safety emergency care in pediatric population. Bogotá DC: Colombia Department of Health and Social Protection; 2010.
7. Ordoñez JE. Diagnostic evaluation before discharge. Bogotá DC: Colombia Department of Health and Social Protection; 2010.
8. Ordoñez JE. Report security system in the intensive care unit. Bogotá DC Colombia Department of Health and Social Protection; 2010.
9. Segura AM, Ordoñez JE. Prevalence of use, risk of addiction to psychoactive substances and joy gamming among college students, Valle de Aburrá, 2009. Medellin: Carisma; 2011.